Investment Q&A

Q: Shareholders of Prometic are being offered a rights issuance where each existing share owned will allow you to buy 20 shares at 1.5 cents. It is trading at 7 cents now real time. Am I missing something or should I jump at the deal. I thought the trading price would instantly come down to the dilution price mentioned in the release.

Q: Prometric announced a restructuring today , It seems like a lot of parts to it.
Can you explain the elements to it and point out the positives and negatives to the deal.
It seems more complicated then the Bellatrix deal.
Thanks

Q: we have seen this stock performing better. Can you comment please

Q: What do you think about BMY at this time? Debt going to be a problem? Recent actions re Celgene positive in your opinion? Thanks

Q: GIVEN THE MESS THAT IS COMING IN THE MAY MEETING, WHAT DO YOU SEE HAPPENING? IS THERE A BUYING OPPORTUNITY HERE IF THERE IS FAITH IN GUD.....OR A SIT TIGHT... OR A SELL?
THANKS IN ADVANCE.

Q: ARKG :ARK Genomic Revolution ETF ... I have done very well and continue to do well with this etf which invests in leading edge companies in applied biotechnology . Oddly, you haven’t ever commented on this etf and I can’t even enter it in my analytics package .

Q: Can you provide any info on this NYSE company? Small penny stock company promoting a new insulin device.

Appreciate your insight.

Paul F.

Q: Would you recommend this US company?

Q: This Health Care ETF has an unusually high yield. Why? Is it because of return of capital or some other source?

Q: Good morning 5i Team

This is a general question about secondary share offerings like the one issued by Savaria recently. In coming up with the offering price, is it typically based on a fundamental analysis of the corporations value or is it just a negotiated discount to the current market price?

Thanks as always.
Peter

Q: Good Morning
Is this deal with SIS today a positive ? Is the family involvement in this deal a positive development for the company ?
Thank You
Clarence

Q: In mid Feb, IRTC reported another strong quarter and issued a better than expected 2019 guidance. However, about a month later a (short?) report stated that the main IRTC product could face a Medicare reimbursement cut of 45-65%, possibly by the latter half of 2021. Do you know if IRTC has publicly addressed this issue? Whether IRTC has or has not done so, is it wise to simply exit the position and move on to another health care stock? Thanks in advance for your input. James.

Q: Following close scrutiny of the available information to date, I have decided to support Johnathan Goodman in his battle with Medison. This is essentially a war between two men as no one else at Knight or Medison has more than 35000 shares (one person) and the rest have basically none. Goodman has double the number as Medison. I predict Goodman will add to his position before May 7 - he could afford as many shares as he wants/needs to succeed.
However, kudos to Jakobsohn, despite my extreme cynicism towards his motives - he will control the 28% of his company that knight owns plus get control of almost $800M in cash that he did NOT raise, Goodman did - as this process has unquestionably devalued Goodman's reputation and I am sure he will be working at full potential to restore it and long before his tired grandchildren timeline evolves. When/if he wins, he could do a $2B deal the next day as raising any extra funds would receive widespread market support. Can Jakobsohn claim the same?

Q: How much cash does Gud have compared to its market cap and do they have any growing cash generating product. Thinking of selling position and splitting the proceeds with zynex and viemed.

Q: Like many long suffering investors, I am really getting fed up with this stock. I watched a recent interview on BNN with Jonathan Goodman and was not impressed. He had an opportunity to justify why GUD was a public company and completely failed to do so. His message seemed to be if you are not investing for your grandchildren's financial future you might as well forget this stock. I think GUD should at least initiate an initial and rising dividend policy since it has failed to invest much of the large pool of cash being reserved for acquisitions. What do you think of these odds. Thanks.

Q: Could you explain the differences between these two ETFs, if you can call CGOC an ETF. Specifically as to what they invest in, are they actively managed, and their level of risk compared to each other? Your preference of the two, for someone who has a high risk tolerance, who wishes to have some exposure to the industry?

Q: Hi,

Can I get your opinion on SBIO? It's been treating me pretty well.

Thanks

Q: With the stock up 45% in the last year, would you still consider Merck a buy for a long term hold?

Q: I am tired of waiting for GUD to do something. I have 50,000 shares; what would you suggest in trying to sell these?

Q: Hello,

With the news this morning that Profound Medical's clinical trial proved 96% effective for the prostate cancer patients involved in the study, do you see this as a buy? Or is it still considerably risky, given that FDA approval could take some time or be denied?

Thank you.

Brad